AIM ImmunoTech Inc. (AMEX:AIM) is Gaining Momentum on Earnings Catalyst

AIM ImmunoTech Inc. (AMEX:AIM) is Gaining Momentum on Earnings Catalyst


The AIM ImmunoTech Inc. (AIM) shares are trading at lower $3.04 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $7.11 and the low is $0.38. Over the last 52 weeks, AIM is down -57.24% while the S&P 500 is up 0.29%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, AIM reported a profit of $-0.16 million. AIM ImmunoTech Inc. also saw revenues decrease to $45000.0. In addition, AIM has free cash flow of -$3.07 million as of 03-2020. The company’s EBITDA came in at -$2.76 million which compares well with its peers.

AIM Return on Equity (ROE) is -61.50%, and its Return on Assets is -40.30%. All told, it is clear that, AIM needs to be on your watchlist.

Find out when AIM reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. AIM has a short ratio of 0.47 and outstanding shares of 32.62M.

Company Outlook

AIM has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 11.38 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -2.55. AIM ImmunoTech Inc. AIM also noted assets of $42.41 million at the end of the last quarter. Investors should also keep an eye on sector updates as AIM has historically followed its peers on positive news.

All told, AIM ImmunoTech Inc. AIM has strung together solid data and demonstrated underlying fundamentals. At its current valuation, AIM represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

AIM ImmunoTech Inc. AIM is now commanding a market cap of 101.81M and a float of 28.77M. AIM is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of AIM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in AIM, either long or short, and we have not been compensated for this article.